Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster

NEW YORK and MAINZ, GERMANY, August 31, 2022— Pfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of a 30-µg booster dose of the Pfizer-BioNTech COVID-19...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials